CF PharmTech (HKG:2652) said its inhalation formulation production base in Suzhou passed a good manufacturing practice inspection conducted by the drug regulator of a member country of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme, according to a Thursday Hong Kong bourse filing.
The inspection covered the facility's production management and quality control systems, premises, equipment, data integrity, and computerized systems.
Shares of the pharmaceutical firm were up over 1% in Friday morning trade.